Notch1 silencing inhibits proliferation and invasion in SGC-7901 gastric cancer cells

Molecular Medicine Reports

Volumn 9, Issue 4, 2014, Pages 1153-1158

  Wei, Guangbing ^a   Chang, Yuanhong ^a   Zheng, Jianbao ^a   He, Sai ^a   Chen, Nanzheng ^a   Wang, Xiaolong ^a   Sun, Xuejun ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Gastric cancer; Invasion; Notch1; Proliferation; Small interfering RNA

Indexed keywords

CYCLIN A1; CYCLIN D1; CYCLIN DEPENDENT KINASE 2; CYCLOOXYGENASE 2; GELATINASE A; MESSENGER RNA; NOTCH1 RECEPTOR; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER INHIBITION; CONTROLLED STUDY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TUMOR INVASION; WESTERN BLOTTING;

CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLOOXYGENASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; HUMANS; MATRIX METALLOPROTEINASE 2; NEOPLASM INVASIVENESS; RECEPTOR, NOTCH1; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 84896520119     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2014.1920     Document Type: Article

References (29)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63: 11-30, 2013.
2. Chen W, Zheng R, Zhang S, Zhao P, Li G, Wu L and He J: Report of incidence and mortality in China cancer registries, 2009. Chin J Cancer Res 25: 10-21, 2013.
3. Oba K, Paoletti X, Bang YJ, Bleiberg H, Burzykowski T, Fuse N, Michiels S, Morita S, Ohashi Y, Pignon JP, et al: Role of chemotherapy for advanced/recurrent gastric cancer: an individual-patient-data meta-analysis. Eur J Cancer 49: 1565-1577, 2013.
4. Kopan R and Ilagan MX: The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 137: 216-233, 2009.
5. Borggrefe T and Liefke R: Fine-tuning of the intracellular canonical Notch signaling pathway. Cell Cycle 11: 264-276, 2012.
6. South AP, Cho RJ and Aster JC: The double-edged sword of Notch signaling in cancer. Semin Cell Dev Biol 23: 458-464, 2012.
7. Dai Q, Andreu-Agullo C, Insolera R, Wong LC, Shi SH and Lai EC: BEND6 is a nuclear antagonist of Notch signaling during self-renewal of neural stem cells. Development 140: 1892-1902, 2013.
8. Mullendore ME, Koorstra JB, Li YM, Offerhaus GJ, Fan X, Henderson CM, Matsui W, Eberhart CG, Maitra A and Feldmann G: Ligand-dependent Notch signaling is involved in tumor initiation and tumor maintenance in pancreatic cancer. Clin Cancer Res 15: 2291-2301, 2009.
9. Bolos V, Mira E, Martinez-Poveda B, Luxan G, Canamero M, Martinez-A C, Manes S and de la Pompa JL: Notch activation stimulates migration of breast cancer cells and promotes tumor growth. Breast Cancer Res 15: R54, 2013.
10. Piazzi G, Fini L, Selgrad M, Garcia M, Daoud Y, Wex T, Malfertheiner P, Gasbarrini A, Romano M, Meyer RL, et al: Epigenetic regulation of Delta-Like1 controls Notch1 activation in gastric cancer. Oncotarget 2: 1291-1301, 2011.
11. Wang Z, Li Y and Sarkar FH: Notch signaling proteins: legitimate targets for cancer therapy. Curr Protein Pept Sci 11: 398-408, 2010.
12. Sun Y, Gao X, Liu J, Kong QY, Wang XW, Chen XY, Wang Q, Cheng YF, Qu XX and Li H: Differential Notch1 and Notch2 expression and frequent activation of Notch signaling in gastric cancers. Arch Pathol Lab Med 135: 451-458, 2011.
13. Li DW, Wu Q, Peng ZH, Yang ZR and Wang Y: Expression and significance of Notch1 and PTEN in gastric cancer. Ai Zheng 26: 1183-1187, 2007 (In Chinese).
14. Li X, Ma Q, Xu Q, Duan W, Lei J and Wu E: Targeting the cancer-stroma interaction: a potential approach for pancreatic cancer treatment. Curr Pharm Des 18: 2404-2415, 2012.
15. Shuman Moss LA, Jensen-Taubman S and Stetler-Stevenson WG: Matrix metalloproteinases: changing roles in tumor progression and metastasis. Am J Pathol 181: 1895-1899, 2012.
16. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, et al: Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773: 1263-1284, 2007. (Pubitemid 47125967)
17. Li T, Kon N, Jiang L, Tan M, Ludwig T, Zhao Y, Baer R and Gu W: Tumor suppression in the absence of p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell 149: 1269-1283, 2012.
18. Cheng HH, Kuo CC, Yan JL, Chen HL, Lin WC, Wang KH, Tsai KK, Guven H, Flaberg E, Szekely L, et al: Control of cyclooxygenase-2 expression and tumorigenesis by endogenous 5-methoxytryptophan. Proc Natl Acad Sci USA 109: 13231-13236, 2012.
19. de Moraes E, Dar NA, de Moura Gallo CV and Hainaut P: Cross-talks between cyclooxygenase-2 and tumor suppressor protein p53: balancing life and death during inflammatory stress and carcinogenesis. Int J Cancer 121: 929-937, 2007. (Pubitemid 47101627)
20. Yeh TS, Wu CW, Hsu KW, Liao WJ, Yang MC, Li AF, Wang AM, Kuo ML and Chi CW: The activated Notch1 signal pathway is associated with gastric cancer progression through cyclooxygenase-2. Cancer Res 69: 5039-5048, 2009.
21. Portanova P, Notaro A, Pellerito O, Sabella S, Giuliano M and Calvaruso G: Notch inhibition restores TRAIL-mediated apoptosis via AP1-dependent upregulation of DR4 and DR5 TRAIL receptors in MDA-MB-231 breast cancer cells. Int J Oncol 43: 121-130, 2013.
22. Zhou H, Luo Y, Chen JH, Hu J, Luo YZ, Wang W, Zeng Y and Xiao L: Knockdown of TRB3 induces apoptosis in human lung adenocarcinoma cells through regulation of Notch 1 expression. Mol Med Rep 8: 47-52, 2013.
23. Kristoffersen K, Villingshoj M, Poulsen HS and Stockhausen MT: Level of Notch activation determines the effect on growth and stem cell-like features in glioblastoma multiforme neurosphere cultures. Cancer Biol Ther 14: 625-637, 2013.
24. Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A and Rajeshkumar NV: Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335: 41-51, 2013.
25. Kang H, An HJ, Song JY, Kim TH, Heo JH, Ahn DH and Kim G: Notch3 and Jagged2 contribute to gastric cancer development and to glandular differentiation associated with MUC2 and MUC5AC expression. Histopathology 61: 576-586, 2012.
26. Nicolas M, Wolfer A, Raj K, Kummer JA, Mill P, van Noort M, Hui CC, Clevers H, Dotto GP and Radtke F: Notch1 functions as a tumor suppressor in mouse skin. Nat Genet 33: 416-421, 2003. (Pubitemid 36278861)
27. Fanjul-Fernandez M, Folgueras AR, Fueyo A, Balbin M, Suarez MF, Fernandez-Garcia MS, Shapiro SD, Freije JM and Lopez-Otin C: Matrix metalloproteinase Mmp-1a is dispensable for normal growth and fertility in mice and promotes lung cancer progression by modulating inflammatory responses. J Biol Chem 288: 14647-14656, 2013.
28. Kaimal R, Aljumaily R, Tressel SL, Pradhan RV, Covic L, Kuliopulos A, Zarwan C, Kim YB, Sharifi S and Agarwal A: Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 73: 2457-2467, 2013.
29. Shi H, Xu JM, Hu NZ and Xie HJ: Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol 9: 1421-1426, 2003. (Pubitemid 36992325)